CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.18048855

Available online at: http://www.iajps.com Review Article

SEROTONIN ANTAGONISTS AND THEIR ROLE IN NEUROPSYCHIATRIC DISORDERS: A COMPREHENSIVE REVIEW

Rutwik Nandkishor Mahale[1], Gaurav A. Khandare[2], Prashant S. Ade[3], Prathmesh D. Jaulkar[4], Mahesh V. Kekan[5]

[1,2,3,4] MUP's College of Pharmacy, Degaon, Tq. Risod, District Washim, Maharashtra, India.

[5] Associate Professor, M.Pharm, Department of Pharmacology,MUP's College of Pharmacy, Degaon, Tq. Risod, District Washim, Maharashtra, India.

Abstract:

Serotonin (5-hydroxytryptamine, 5-HT) is a key neurotransmitter involved in the regulation of mood, cognition, perception, sleep, and behavior. Dysregulation of serotonergic signaling has been strongly implicated in the pathophysiology of several neuropsychiatric disorders, including schizophrenia, depression, anxiety disorders, bipolar disorder, and migraine. Serotonin antagonists act by selectively or non-selectively blocking specific 5-HT receptor subtypes, thereby modulating abnormal neurotransmission associated with these conditions. Notably, antagonism at 5-HT$_2$A and 5-HT$_2$C receptors has shown therapeutic benefits in the management of psychosis, mood instability, and behavioral disturbances, while also reducing extrapyramidal side effects when used in antipsychotic therapy. This review focuses on the pharmacological basis of serotonin antagonists, their receptor-specific actions, and their clinical relevance in various neuropsychiatric disorders. Recent advances, therapeutic applications, and future prospects of serotonin antagonists in neuropsychiatry are also discussed.

Keywords:*Serotonin antagonists; 5-HT receptors; Neuropsychiatric disorders; Antipsychotic therapy; Mood disorders; Neurotransmission*

Corresponding author:

Rutwik Nandkishor Mahale,
MUP's College of Pharmacy,
Degaon, Tq. Risod, District Washim,
Maharashtra, India.

QR CODE

Please cite this article in press Rutwik Nandkishor Mahale ***et al., Serotonin Antagonists And Their Role In Neuropsychiatric Disorders: A Comprehensive Review,*** *Indo Am. J. P. Sci, 2025; 12(12).*

INTRODUCTION:

1. Serotonergic System

The serotonergic system is one of the most widespread and influential neurotransmitter systems in the human brain. Serotonin (5-hydroxytryptamine, 5-HT) is synthesized primarily in the raphe nuclei of the brainstem and projects extensively to cortical, limbic, and subcortical regions. Through these projections, serotonin regulates a wide range of physiological and psychological functions, including mood, emotion, cognition, sleep–wake cycles, appetite, pain perception, and social behavior. Alterations in serotonergic neurotransmission have long been associated with the development of neuropsychiatric disorders. Unlike neurotransmitters that act through a limited number of receptors, serotonin exerts its effects through multiple receptor subtypes, allowing for highly diverse and sometimes opposing biological actions. This complexity makes the serotonergic system an important but challenging target for psychopharmacological intervention.[1]



Figure 1: serotonergic pathways in the human brain.

2. Serotonin Receptors and Functional Diversity

Serotonin receptors are classified into seven major families ($5\text{-}HT_1$ to $5\text{-}HT_7$), comprising more than fourteen receptor subtypes. Except for the $5\text{-}HT_3$ receptor, which is a ligand-gated ion channel, all serotonin receptors are G-protein-coupled receptors. Each receptor subtype differs in distribution, signal transduction mechanisms, and physiological roles. For example, $5\text{-}HT_1$ receptors are largely inhibitory and associated with anxiolytic and antidepressant effects, whereas $5\text{-}HT_2$ receptors are excitatory and involved in perception, cognition, and psychotic symptoms. This receptor heterogeneity explains why selective modulation of specific serotonin receptors can produce distinct therapeutic outcomes. Understanding receptor-specific functions is therefore crucial for the rational design and clinical use of serotonin antagonists in neuropsychiatric disorders.[2]



Serotonin receptors						
5-HT1	5-HT2	5-HT3	5-HT4	5-HT5	5-HT6	5-HT7
5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT1F	5-HT2A 5-HT2B 5-HT2C	5-HT3A 5-HT3B 5-HT3C 5-HT3D 5-HT3E	5-HT4A 5-HT4B 5-HT4C	5-HT5A 5-HT5B	(No sub-types)	5-HT7A 5-HT7B 5-HT7C 5-HT7D
GPCR Coupled to Gi/o	GPCR Coupled to Gq	Ligand-gated ion channel	GPCR Coupled to Gs	GPCR Coupled to Gi/o	GPCR Coupled to Gs	GPCR Coupled to Gs
↓ Cyclic AMP	↑ Ca2+; PKC Activation		↑ Cyclic AMP	↓ Cyclic AMP	↑ Cyclic AMP	↑ Cyclic AMP
Inhibitory	Stimulatory	Depolarization	Stimulatory	Inhibitory	Stimulatory	Stimulatory

Figure 2: Classification and signaling mechanisms of serotonin (5-HT) receptor subtypes.

3. Concept of Serotonin Antagonism

Serotonin antagonists are agents that inhibit the action of serotonin by blocking its interaction with specific receptor subtypes. Rather than reducing serotonin levels globally, these drugs selectively modulate abnormal receptor activity implicated in disease states. Antagonism at $5\text{-}HT_2A$ and $5\text{-}HT_2C$ receptors is particularly relevant in neuropsychiatry, as overstimulation of these receptors has been linked to hallucinations, delusions, mood dysregulation, and sleep disturbances. By blocking these receptors, serotonin antagonists help restore neurotransmitter balance and improve clinical symptoms. Importantly, serotonin antagonism often complements dopaminergic modulation, especially in antipsychotic therapy, contributing to improved efficacy and reduced adverse effects. This targeted approach highlights the therapeutic advantage of receptor-specific serotonin antagonists over non-selective interventions.[3]

4. Role in Neuropsychiatric Disorders

Neuropsychiatric disorders such as schizophrenia, depression, anxiety disorders, bipolar disorder, and migraine involve complex interactions between multiple neurotransmitter systems. Serotonin plays a central modulatory role in these conditions by influencing dopamine, glutamate, and GABA pathways. In schizophrenia, excessive $5\text{-}HT_2A$ receptor activity contributes to positive symptoms and cognitive dysfunction. In mood and anxiety disorders, serotonergic imbalance affects emotional regulation and stress responsiveness. Serotonin antagonists help normalize these disrupted neural circuits, either as monotherapy or in combination with other psychotropic agents. Their role is particularly significant in atypical antipsychotics, where serotonin antagonism enhances therapeutic outcomes while minimizing extrapyramidal side effects associated with dopamine blockade.[4]

2. Neurobiology of Serotonin in the Central Nervous System

2.1 Synthesis and Distribution of Serotonin

Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter synthesized in the central nervous system from the essential amino acid tryptophan. The biosynthesis occurs through a two-step enzymatic pathway involving tryptophan hydroxylase as the rate-limiting enzyme, followed by aromatic L-amino acid decarboxylase. In the brain, serotonergic neurons are predominantly localized in the raphe nuclei of the brainstem. From these nuclei, extensive projections arise and innervate almost all major brain regions, including the cerebral cortex, limbic system, basal ganglia, hypothalamus, and spinal cord. Due to this widespread distribution, serotonin functions as a modulatory neurotransmitter, influencing large neural networks rather than exerting localized synaptic effects.[5]

2.2 Storage, Release, and Metabolism

After synthesis, serotonin is actively transported into synaptic vesicles and stored until neuronal activation triggers its release into the synaptic cleft. The release of serotonin occurs in response to action potential–induced depolarization and calcium influx. Termination of serotonergic signaling is primarily achieved through reuptake into the presynaptic neuron by the serotonin transporter (SERT). Once reabsorbed, serotonin is either repackaged into vesicles or metabolized by monoamine oxidase (MAO) into inactive metabolites. The tight regulation of these processes ensures balanced serotonergic transmission. Any disruption in synthesis, release, reuptake, or metabolism can lead to altered serotonin availability and abnormal neurotransmission, which is commonly observed in neuropsychiatric disorders.[6]

2.3 Serotonin Receptors and Regional Function

A defining characteristic of the serotonergic system is the presence of multiple receptor subtypes with distinct distributions and signaling mechanisms. Different brain regions express varying profiles of serotonin receptors, allowing serotonin to exert diverse and sometimes opposing effects. In cortical and limbic areas, serotonin plays a key role in regulating mood, emotional processing, cognition, and perception. In contrast, serotonergic activity in the brainstem and hypothalamus contributes to autonomic control, sleep–wake regulation, appetite, and thermoregulation. This receptor and region specificity explains the broad spectrum of behavioral and psychological effects mediated by serotonin.[7]

2.4 Interaction with Other Neurotransmitter Systems

Serotonin does not function in isolation but interacts closely with other neurotransmitter systems such as dopamine, glutamate, and gamma-aminobutyric acid (GABA). Through these interactions, serotonin helps maintain the balance between excitatory and inhibitory signaling in the brain. For example, serotonergic modulation of dopaminergic pathways plays a critical role in reward processing, motivation, and psychotic symptoms. Similarly, serotonin influences glutamatergic neurotransmission involved in learning and memory, as well as GABAergic circuits responsible for inhibitory control. Dysregulation of these interactions contributes significantly to the pathophysiology of neuropsychiatric disorders.[8]

2.5 Relevance to Neuropsychiatric Disorders

In many neuropsychiatric conditions, serotonergic dysfunction arises from abnormal receptor activation rather than simple changes in serotonin concentration. Excessive stimulation of certain serotonin receptors has been associated with hallucinations, delusions, and mood disturbances, while insufficient serotonergic modulation may lead to depression and anxiety. These observations emphasize the importance of receptor-level mechanisms in disease development. A detailed understanding of serotonin neurobiology therefore provides the scientific basis for targeting specific serotonin receptors using antagonists as an effective therapeutic strategy.[9]



Figure 4: Neurobiological pathways of serotonin synthesis, release, and interaction with other neurotransmitter systems in the central nervous system.

3. Classification of Serotonin Antagonists

Serotonin antagonists comprise a diverse group of pharmacological agents that inhibit the action of serotonin by blocking specific 5-HT receptor subtypes. Their classification is primarily based on receptor selectivity and therapeutic application, which determines their role in neuropsychiatric disorders.[10]

3.1 Non-Selective Serotonin Antagonists

Non-selective serotonin antagonists block multiple serotonin receptor subtypes simultaneously. These agents were among the earliest serotonin-blocking drugs developed and exhibit broad pharmacological effects. Due to their lack of receptor specificity, they influence several physiological systems, including the central nervous system and peripheral tissues. While non-selective antagonists can be effective in reducing serotonergic overactivity, their use in neuropsychiatric disorders is limited by adverse effects such as sedation, anticholinergic symptoms, and cardiovascular disturbances. Nevertheless, they have contributed significantly to the understanding of serotonergic involvement in psychiatric conditions and laid the foundation for the development of more selective agents.[11]

3.2 Selective 5-HT$_2$ Receptor Antagonists

Selective antagonists of the 5-HT$_2$ receptor family, particularly 5-HT$_2$A and 5-HT$_2$C receptors, represent the most clinically relevant class in neuropsychiatry. Overactivation of these receptors has been implicated in hallucinations, delusions, mood dysregulation, and sleep disturbances. By selectively blocking these receptors, 5-HT$_2$ antagonists help normalize cortical and limbic neurotransmission. This class is especially important in the pharmacological management of psychotic and mood disorders, as selective antagonism improves therapeutic efficacy while minimizing unwanted systemic effects associated with non-selective blockade.[12]

3.3 5-HT$_3$ Receptor Antagonists

The 5-HT$_3$ receptor is unique among serotonin receptors because it is a ligand-gated ion channel rather than a G-protein-coupled receptor. Antagonists of this receptor primarily act by inhibiting fast excitatory serotonergic signaling. Although 5-HT$_3$ antagonists are widely used as antiemetic agents, emerging evidence suggests their potential role in neuropsychiatric disorders such as anxiety, schizophrenia, and cognitive dysfunction. Their mechanism involves modulation of dopamine and acetylcholine release in key brain regions, thereby indirectly influencing mood and cognition.[13]

3.4 Atypical Antipsychotics with Serotonin Antagonistic Activity

Many modern atypical antipsychotic drugs exert their therapeutic effects through combined dopamine D$_2$ receptor antagonism and serotonin 5-HT$_2$A receptor antagonism. This dual mechanism is considered a major advancement in the treatment of schizophrenia and related disorders. Serotonin antagonism reduces dopaminergic hyperactivity in mesolimbic pathways while preserving dopamine function in nigrostriatal pathways, thereby decreasing extrapyramidal side effects. As a result, atypical antipsychotics demonstrate improved tolerability and broader efficacy against both positive and negative symptoms.[14]

3.5 Clinical Significance of Classification

The classification of serotonin antagonists highlights the importance of receptor selectivity in determining therapeutic outcomes and safety profiles. Understanding these classes allows clinicians and researchers to rationally select agents based on disease pathology, symptom profile, and patient tolerance. This receptor-based classification also guides future drug development aimed at achieving targeted serotonergic modulation with minimal adverse effects.[15]

Table 1: Classification of Serotonin Antagonists and Their Neuropsychiatric Relevance[16,17]

Class of Serotonin Antagonist	Primary Receptor Target	Major Neuropsychiatric Application	Key Therapeutic Advantage
Non-selective antagonists	Multiple 5-HT receptors	Limited psychiatric use	Broad serotonergic inhibition
Selective 5-HT$_2$ antagonists	5-HT$_2$A / 5-HT$_2$C	Schizophrenia, mood disorders	Improved efficacy, fewer side effects
5-HT$_3$ antagonists	5-HT$_3$	Anxiety, cognitive disorders	Modulation of excitatory signaling
Atypical antipsychotics	5-HT$_2$A + D$_2$	Psychotic disorders	Reduced extrapyramidal symptoms

4. Mechanism of Action of Serotonin Antagonists

Serotonin antagonists exert their therapeutic effects by selectively inhibiting the activation of specific 5-HT receptor subtypes involved in abnormal neurotransmission. Rather than reducing overall serotonin levels, these agents act at the receptor level to normalize dysregulated neural circuits implicated in neuropsychiatric disorders.[18]

4.1 Receptor-Level Antagonism

The primary mechanism of serotonin antagonists involves competitive or non-competitive blockade of serotonin receptors, most notably the 5-HT$_2$A and 5-HT$_2$C subtypes. These receptors are widely distributed in cortical and limbic regions associated with perception, mood, and cognition. Excessive stimulation of these receptors has been linked to hallucinations, delusions, emotional instability, and sleep disturbances. By preventing serotonin from binding to these receptors, antagonists reduce pathological excitatory signaling and help restore normal neuronal activity. This receptor-specific antagonism allows for targeted modulation of serotonergic pathways without causing global neurotransmitter suppression.[19]



Figure 6: Receptor-level mechanism of action of serotonin antagonists and their modulatory effects on serotonergic and dopaminergic pathways in the brain.

4.2 Modulation of Cortical and Limbic Circuits

Serotonin antagonists play a crucial role in regulating cortical and limbic circuitry, which is often disrupted in neuropsychiatric conditions. In the prefrontal cortex, excessive serotonergic excitation can impair cognitive processing and emotional regulation. Antagonism of 5-HT_2 receptors reduces this overactivation, thereby improving cognitive clarity and behavioral control. In limbic structures such as the amygdala and hippocampus, serotonin antagonists help stabilize emotional responses and reduce anxiety-related hyperreactivity. Through these actions, serotonin antagonists contribute to the normalization of higher brain functions.[20]

4.3 Dopamine–Serotonin Interaction

An important aspect of the mechanism of serotonin antagonists is their indirect influence on dopaminergic neurotransmission. Serotonin exerts inhibitory control over dopamine release in certain brain regions. Blockade of specific serotonin receptors, particularly 5-HT_2A receptors, leads to enhanced dopamine release in the prefrontal cortex and nigrostriatal pathways. This effect is especially beneficial in the treatment of psychotic disorders, as it helps reduce positive symptoms while preserving motor function. The dopamine–serotonin balance achieved through receptor antagonism is a key factor in the improved efficacy and tolerability of modern antipsychotic drugs.[21]

4.4 Impact on Adverse Effects and Tolerability

Serotonin antagonism also contributes to a favorable side-effect profile in neuropsychiatric pharmacotherapy. By modulating serotonin-dopamine interactions, these agents reduce the risk of extrapyramidal symptoms commonly associated with pure dopamine antagonists. Additionally, selective serotonin antagonists tend to produce fewer sedative and autonomic side effects compared to non-selective agents. This improved tolerability enhances patient adherence and supports long-term treatment outcomes.[22]

4.5 Therapeutic Implications

The mechanism of action of serotonin antagonists underscores their importance as rational therapeutic agents in neuropsychiatry. By targeting receptor-specific abnormalities and restoring neurotransmitter balance, these drugs address both symptom control and functional improvement. Understanding these mechanisms provides a strong scientific basis for their clinical application and ongoing development.[23]

5. Role of Serotonin Antagonists in Neuropsychiatric Disorders

Serotonin antagonists have gained significant importance in the management of neuropsychiatric disorders due to their ability to modulate dysfunctional serotonergic signaling and restore neurotransmitter balance. Their therapeutic role varies across disorders depending on the underlying pathophysiology and receptor involvement.[24]

5.1 Schizophrenia and Psychotic Disorders

Schizophrenia is strongly associated with dysregulation of both serotonergic and dopaminergic systems. Overactivation of 5-HT_2A receptors in the cerebral cortex has been implicated in hallucinations, delusions, and cognitive disturbances. Serotonin antagonists, particularly those targeting 5-HT_2A receptors, reduce excessive cortical excitation and indirectly enhance dopamine release in the prefrontal cortex. This dual effect contributes to the improvement of positive symptoms while also addressing negative and cognitive symptoms. The incorporation of serotonin antagonism into atypical antipsychotic therapy has significantly reduced extrapyramidal side effects compared to conventional dopamine antagonists, thereby improving overall treatment outcomes.[25]

5.2 Depression and Mood Disorders

In mood disorders, serotonergic imbalance affects emotional regulation, motivation, and sleep patterns. While antidepressants traditionally aim to enhance serotonergic transmission, selective serotonin antagonists play a complementary role by blocking receptor subtypes associated with anxiety, insomnia, and emotional dysregulation. Antagonism of specific serotonin receptors helps stabilize mood, improve sleep architecture, and reduce agitation. In treatment-resistant depression, serotonin antagonists are often used as adjuncts to enhance therapeutic response and improve tolerability.[26]

5.3 Anxiety Disorders

Anxiety disorders are characterized by heightened emotional reactivity and dysregulated stress responses. Excessive serotonergic signaling in limbic regions such as the amygdala contributes to fear, panic, and anticipatory anxiety. Serotonin antagonists help dampen this hyperactivity by selectively blocking excitatory serotonin receptors. Through modulation of serotonergic input to GABAergic and dopaminergic neurons, these agents promote anxiolytic effects and emotional stabilization, making them useful either alone or in combination with other anxiolytic medications.[27]

5.4 Bipolar Disorder

Bipolar disorder involves alternating episodes of mania and depression, reflecting instability in neurotransmitter systems. During manic phases, excessive serotonergic and dopaminergic activity contributes to heightened mood, impulsivity, and reduced sleep. Serotonin antagonists help control manic symptoms by limiting receptor-mediated excitation and stabilizing neural circuits. Their mood-stabilizing properties also reduce the risk of switching between mood states when used alongside mood stabilizers.[28]

5.5 Migraine and Related Neuropsychiatric Conditions

Serotonin plays a crucial role in neurovascular regulation and sensory processing, both of which are involved in migraine pathophysiology. Certain serotonin antagonists help prevent migraine attacks by inhibiting receptor-mediated vasodilation and abnormal sensory transmission. Additionally, their effects on mood and anxiety make them beneficial in patients with comorbid psychiatric symptoms.[29]

6.Clinically Important Serotonin Antagonists: Therapeutic Applications and Safety Considerations

Serotonin antagonists are widely used in neuropsychiatric practice due to their receptor-specific actions and favorable therapeutic profiles. Their clinical importance lies not only in symptom control but also in improved tolerability compared to earlier psychotropic agents. However, like all central nervous system drugs, their use is associated with certain limitations and safety concerns that must be carefully considered.[30]

Clinically, serotonin antagonists are most prominently represented by drugs that block $5\text{-}HT_2$ receptors, either selectively or as part of a multi-receptor pharmacological profile. Several atypical antipsychotics exert serotonin antagonistic activity alongside dopamine D_2 receptor blockade. This dual mechanism is particularly beneficial in schizophrenia and related psychotic disorders, as serotonin antagonism reduces cortical excitability while indirectly modulating dopamine release. As a result, these agents are effective against positive symptoms such as hallucinations and delusions and also show benefits in managing negative symptoms and cognitive deficits. In mood and anxiety disorders, certain serotonin antagonists are used as adjunctive therapy to improve sleep quality, reduce agitation, and enhance emotional stability.

Beyond psychosis and mood disorders, serotonin antagonists have demonstrated utility in conditions such as migraine and behavioral disturbances associated with neurological disorders. By inhibiting receptor-mediated neurovascular and sensory mechanisms, these agents help reduce headache frequency and intensity while also addressing comorbid anxiety or depressive symptoms. The broad therapeutic spectrum of serotonin antagonists reflects the central role of serotonergic modulation in brain function.[30]

Despite their advantages, serotonin antagonists are not free from adverse effects. Common side effects include sedation, weight gain, metabolic disturbances, and anticholinergic effects, particularly with agents that have non-selective receptor profiles. Long-term use of certain serotonin antagonists, especially atypical antipsychotics, may increase the risk of metabolic syndrome, including dyslipidemia and impaired glucose tolerance. Cardiovascular effects such as orthostatic hypotension can also occur due to peripheral receptor blockade. Additionally, drug–drug interactions are an important consideration, as many serotonin antagonists are metabolized by hepatic enzymes and may interact with other psychotropic or systemic medications.[31]

Therefore, the clinical use of serotonin antagonists requires a careful balance between therapeutic benefits and potential risks. Individualized drug selection, dose optimization, and regular monitoring are essential to maximize efficacy while minimizing adverse outcomes. Continued research aimed at developing more receptor-selective agents is expected to further improve the safety and effectiveness of this important class of neuropsychiatric drugs.[32]

Table 2: Clinically Important Serotonin Antagonists, Therapeutic Uses, and Safety Considerations[33,34]

Drug	Major Receptor Target	Primary Neuropsychiatric Use	Adverse Effects
Selective 5-HT_2 antagonists	5-HT_2A / 5-HT_2C	Mood disorders, psychosis	Sedation, dizziness
Atypical antipsychotics	5-HT_2A + D_2	Schizophrenia, bipolar disorder	Weight gain, metabolic effects
5-HT_3 antagonists	5-HT_3	Anxiety, cognitive symptoms	Headache, constipation
Non-selective antagonists	Multiple 5-HT receptors	Limited psychiatric use	Anticholinergic effects

SUMMARY AND CONCLUSION:

Serotonin antagonists represent an important class of neuropsychiatric therapeutics due to their ability to selectively modulate serotonergic signaling at the receptor level. Unlike strategies that globally alter serotonin concentration, receptor-specific antagonism allows targeted correction of dysfunctional neural pathways implicated in psychiatric and neurological disorders. Antagonism of key serotonin receptors, particularly 5-HT_2 subtypes, has demonstrated significant clinical benefits in the management of schizophrenia, mood disorders, anxiety disorders, bipolar disorder, and migraine. The integration of serotonin antagonism with dopaminergic modulation, as seen in atypical antipsychotics, has improved therapeutic efficacy while reducing adverse motor effects. Despite their clinical value, the use of serotonin antagonists requires careful consideration of safety issues, including metabolic and cardiovascular risks. Overall, serotonin antagonists continue to play a vital role in neuropsychiatry, offering effective symptom control and improved patient outcomes when appropriately selected and monitored.

Future Scope

Future research on serotonin antagonists is expected to focus on the development of highly receptor-selective agents with improved safety profiles. Advances in molecular pharmacology and neuroimaging may enable personalized treatment strategies based on individual receptor expression patterns. The exploration of novel serotonin receptor targets and combination therapies may further expand therapeutic applications, particularly in treatment-resistant neuropsychiatric disorders. Additionally, integrating pharmacogenomics with clinical practice could optimize drug response and minimize adverse effects, enhancing the overall effectiveness of serotonergic modulation in neuropsychiatric care.

REFERENCES:

1. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355–366.
2. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108(5):1614–1641.
3. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46(2):157–203.
4. Müller CP, Jacobs BL. Handbook of the Behavioral Neurobiology of Serotonin. 2nd ed. London: Academic Press; 2010.
5. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(2 Suppl):106S–115S.
6. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215–235.
7. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013;137(1):119–131.
8. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083–1152.
9. Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks. Front Integr Neurosci. 2013;7:25.
10. Howland RH. Cyproheptadine as a serotonin antagonist. J Psychosoc Nurs Ment Health Serv. 2014;52(4):11–14.
11. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353–359.
12. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int Rev Psychiatry. 2007;19(4):357–368.
13. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466–476.
14. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59–67.

15. Schatzberg AF, Nemeroff CB. Textbook of Psychopharmacology. 5th ed. Washington DC: American Psychiatric Publishing; 2017.
16. Deakin JFW. Depression and antisense serotonin mechanisms. J Psychopharmacol. 2003;17(2):97–103.
17. Cowen PJ. Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci. 2008;29(9):433–436.
18. Graeff FG, Guimarães FS, De Andrade TGCS, Deakin JFW. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54(1):129–141.
19. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12(Suppl 1):2–19.
20. Millan MJ. Serotonin $5\text{-}HT_2C$ receptors as a target for the treatment of depressive and anxious states. Psychopharmacology (Berl). 2005;178(4):509–529.
21. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. Cloning of a novel human serotonin receptor ($5\text{-}HT_2B$). J Biol Chem. 1993;268(31):23422–23426.
22. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev. 1992;72(1):165–229.
23. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of ketamine on glutamate and dopamine systems. Arch Gen Psychiatry. 1994;51(3):199–214.
24. Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, Skibicka KP. Serotonin receptor antagonists improve dopamine release. Neuropharmacology. 2014;85:511–521.
25. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of atypical antipsychotics. Neuropsychopharmacology. 1996;14(2):87–96.
26. Kroeze WK, Hufeisen SJ, Popadak BA, Renock S, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts antipsychotic-induced weight gain. J Pharmacol Exp Ther. 2003;307(1):130–138.
27. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
28. Reynolds GP. The pharmacology of atypical antipsychotic drugs. J Psychopharmacol. 2004;18(3):340–347.
29. Cryan JF, Leonard BE. $5\text{-}HT_1A$ and beyond: the role of serotonin receptors in depression and anxiety. Hum Psychopharmacol. 2000;15(2):113–135.
30. Peroutka SJ. Serotonin receptors in migraine. Neurology. 1990;40(7 Suppl 2):S7–S11.
31. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine. Brain. 1993;116(3): 617–639.
32. Mylecharane EJ. Serotonin receptors and migraine therapy. J Neurol. 1991;238(Suppl 1):S45–S52.
33. Griebel G. 5-HT receptor antagonists as anxiolytic agents. Pharmacol Ther. 1995;65(3):319–395.
34. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge: Cambridge University Press; 2013.